Vutrisiran reduces mortality in transthyretin amyloidosis with cardiomyopathy
1. Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with transthyretin amyloidosis ...
Tag: Cardiomyopathy
Aficamten improves oxygen uptake in patients with obstructive hypertrophic cardiomyopathy
1. In this randomized controlled trial, aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) ...
#VisualAbstract: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. ...
#VisualAbstract: Acoramidis is an efficacious treatment for transthyretin amyloid cardiomyopathy compared to placebo
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Acoramidis slows disease progression in transthyretin amyloid cardiomyopathy
1. In this randomized controlled trial, patients with transthyretin (TTR) amyloid cardiomyopathy exposed to acoramidis had slower disease progression than ...
#VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events
©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. ...
Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events
1. In this randomized controlled trial, the antibody NI006 for the treatment of transthyretin amyloid cardiomyopathy (ATTR) showed no associated drug-related ...
#VisualAbstract: Transcatheter repair of mitral regurgitation secondary to cardiomyopathy is safe and effective
1. In this randomized controlled trial, patients who received transcatheter repair of mitral regurgitation secondary to cardiomyopathy had good safety ...
Transcatheter repair of mitral regurgitation secondary to cardiomyopathy is safe and effective
1. In this randomized controlled trial, patients who received transcatheter repair of mitral regurgitation secondary to cardiomyopathy had good safety ...
Mavacamten improves function and quality of life in patients with symptomatic hypertrophic obstructive cardiomyopathy
1. Compared to placebo, patients treated with mavacamten for 30 weeks showed significant improvements on the KCC Questionnaire which evaluates ...